Thus, combined treatment including a GLP-1 RAs and an SGLT2-1, with or without metformin, should be the best choice to start therapy for T2DM with CVRFs (obesity, hypertension, dyslipidemia) because, in addition to reducing glucose levels, body fat will also be decreased as well BP and cardiovascular risk. This evidence concerns the gene GLP1R and hypertensive disorder.